HCMV Pentameric Protein Complex Purification via Segmented Chromatography
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods have been unable to purify complexes comprising human cytomegalovirus (HCMV) glycoproteins such as the trimeric gH/gL/gO complex or the pentameric gH/gL/pUL128/pUL130/pUL131A complex, which are essential for vaccine development and diagnostic applications.
Innovation Solution
The recombinant expression and purification of HCMV membrane protein complexes, specifically the pentameric complex comprising gH, gL, pUL128, pUL130, and pUL131A, are achieved by growing cells expressing these proteins in a growth medium and subsequent purification, resulting in high yields and immunogenic compositions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If current purification methods are used, then the process is simple, but the complexes comprising HCMV glycoproteins cannot be purified
Solution Approach 1:
The patent uses a detergent solubilization step as an intermediary process to extract the membrane protein complexes from the viral envelope while maintaining their integrity. This intermediary step enables the separation of complexes from other viral components without direct harsh purification methods that would denature the proteins.
Solution Approach 2:
The patent employs controlled changes in detergent concentration, pH, and temperature during the purification process to selectively solubilize and purify the glycoprotein complexes. By adjusting these parameters, the method achieves high-resolution separation of the complexes while maintaining their native structure and function.
2Reliability
If no purified complexes are available, then vaccine development is hindered, but producing purified complexes has not been achieved
Solution Approach 1:
The patent performs preliminary enrichment of HCMV-infected cells before purification, concentrating the viral particles and their associated glycoprotein complexes. This preliminary action increases the availability of target complexes for subsequent purification steps, ensuring sufficient material for vaccine development while maintaining high yields.
Solution Approach 2:
The patent produces multiple copies of the glycoprotein complexes through viral replication in cultured cells. By infecting host cells with HCMV and allowing viral replication, the system naturally generates abundant copies of the target complexes, which are then purified for vaccine applications.
3Manufacturing precision
If traditional purification methods are applied, then the process is straightforward, but the complexes remain impure or undetected
Solution Approach 1:
The patent divides the purification process into distinct sequential steps: cell lysis, detergent solubilization, affinity chromatography, and size-exclusion chromatography. Each step targets specific contaminants or complex components, progressively increasing purity. This segmented approach achieves high purification precision while keeping each individual step relatively simple and manageable.
Data Source
Figure 1
Figure 2
Figure 3
AI summary
This disclosure provides an isolated human cytomegalovirus (HCMV) membrane protein complex, wherein said complex comprises gH, gL and at least one more HCMV glycoprotein. In some embodiments the complex consists of gH,gL and gO. In other embodiments the complex consists of gH, gL, p UL128, p UL130 and p UL131A. The disclosure also provides processes for expressing and purifying said complexes, and subsequent uses of said complexes in immunogenic compositions and vaccines.